compound r 3 amino 1 hydroxy 3 4 dihydroquinolin 2 1h one pf 04859989 (Pfizer Inc)
86
Structured Review
Pfizer Inc
compound r 3 amino 1 hydroxy 3 4 dihydroquinolin 2 1h one pf 04859989
Compound R 3 Amino 1 Hydroxy 3 4 Dihydroquinolin 2 1h One Pf 04859989, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+4/05+1+1+1+10+11+11s+12+12r+13+13+2+2+2+3+3+3+4+4+4+5+6+7+7+8+fluoro+fluorophenyl+methyl+one+tetraen+triazatricyclo+triazol+trideca+yl/bio_rxiv__64898__2026__05__18__726114-26-1-12
Average 86 stars, based on 1 article reviews
Compound R 3 Amino 1 Hydroxy 3 4 Dihydroquinolin 2 1h One Pf 04859989, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+4/05+1+1+1+10+11+11s+12+12r+13+13+2+2+2+3+3+3+4+4+4+5+6+7+7+8+fluoro+fluorophenyl+methyl+one+tetraen+triazatricyclo+triazol+trideca+yl/bio_rxiv__64898__2026__05__18__726114-26-1-12
Average 86 stars, based on 1 article reviews
compound r 3 amino 1 hydroxy 3 4 dihydroquinolin 2 1h one pf 04859989 - by Bioz Stars,
2026-10
86/100 stars
Images
1) Product Images from "Auxin is metabolized through kynurenine in Hypericum perforatum L"
Article Title: Auxin is metabolized through kynurenine in Hypericum perforatum L
Journal: bioRxiv
doi: 10.64898/2026.05.18.726114
Figure Legend Snippet: (A) Schematic representation of major tryptophan (Trp)-derived metabolic pathways, including the kynurenine pathway (center), the indole-3-pyruvic acid (IPA)–indole-3-acetic acid (IAA) pathway, and the tryptamine– serotonin–melatonin branch (top). Solid, dashed, and double boxes indicate metabolites reported in animals, plants, or both, respectively. Enzymes are indicated at each step: IDO1/IDO2 (indoleamine 2,3-dioxygenase), TDO (tryptophan 2,3-dioxygenase), AFMID (arylformamidase), KAT (kynurenine aminotransferase), TDC (tryptophan decarboxylase), TAA1/TAR (tryptophan aminotransferase), KYNU (kynureninase), KMO (kynurenine 3-monooxygenase), HAAO (3-hydroxyanthranilate 3,4-dioxygenase), ACMSD (α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase), and QPRT (quinolinate phosphoribosyltransferase). Inhibitor targets are indicated at the corresponding steps: JM6 and RO 61-8048 inhibit KMO, and PF-04859989 inhibits KAT. (B) Chemical structures of the kynurenine pathway metabolites quantified in this study: kynurenine, kynurenic acid (KYNA), and 3-hydroxyanthranilic acid (3-HAA). (C) Chemical structures of the inhibitors used in this study. Core structural differences between JM6 and RO 61-8048 are highlighted in red.
Techniques Used: Derivative Assay
![( A) Representative images of explants cultured on MSO (control), kynurenine (KYN), indole-3-acetic acid (IAA), and IAA combined with inhibitors (IAA + JM6, IAA + PF-04859989 [PF], and IAA + RO 61-8048 [RO]). Scale bar = 1 cm (B) Rooting frequency, (C) internodal length (cm per node), (D) root number, and (E) maximum root length (cm) of explants under each treatment. For rooting frequency (B), bars represent mean proportion rooted ± SE. For (C–E), boxplots represent median (center line), interquartile range (box), and range (whiskers). Differences relative to the MSO control were evaluated using Dunnett-adjusted contrasts (p < 0.05; n = 12–18 per treatment).](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_14/10__64898_slash_2026__05__18__726114/10__64898_slash_2026__05__18__726114___F2.large.jpg "... IAA combined with inhibitors (IAA + JM6, IAA + PF-04859989 [PF], and IAA + RO 61-8048 [RO]). ...")
Figure Legend Snippet: ( A) Representative images of explants cultured on MSO (control), kynurenine (KYN), indole-3-acetic acid (IAA), and IAA combined with inhibitors (IAA + JM6, IAA + PF-04859989 [PF], and IAA + RO 61-8048 [RO]). Scale bar = 1 cm (B) Rooting frequency, (C) internodal length (cm per node), (D) root number, and (E) maximum root length (cm) of explants under each treatment. For rooting frequency (B), bars represent mean proportion rooted ± SE. For (C–E), boxplots represent median (center line), interquartile range (box), and range (whiskers). Differences relative to the MSO control were evaluated using Dunnett-adjusted contrasts (p < 0.05; n = 12–18 per treatment).
Techniques Used: Cell Culture, Control
Figure Legend Snippet: (A–C) Representative extracted ion chromatograms (EICs) of PF-04859989 (A), RO 61-8048 (B), and JM6 (KMO inhibitor II) (C) detected in plant tissue by LC–HRMS. Each panel shows the precursor ion trace at the expected m/z and retention time. (D–F) Relative abundance of PF (D), RO (E), and JM6 (F) in roots and shoots following treatment with MSO (control), inhibitor alone, or IAA + inhibitor. Peak areas are shown as log□□-transformed values. Boxplots represent median (center line), interquartile range (box), and range (whiskers). Signals corresponding to each inhibitor were observed in treated tissues and were not detected in MSO controls. Detection was also observed in IAA co-application treatments.
Techniques Used: Control, Transformation Assay
Figure Legend Snippet: Concentrations of (A, D) kynurenic acid (KYNA), (B, E) kynurenine (KYN), and (C, F) 3-hydroxyanthranilic acid (3-HAA) in shoots (A–C) and roots (D–F) of explants cultured on MSO (control), IAA, or IAA combined with kynurenine pathway inhibitors (IAA + JM6, IAA + PF-04859989, and IAA + RO 61-8048). Concentrations are shown as log□□ (ng g −1 FW). Boxplots represent median (center line), interquartile range (box), and range (whiskers). For shoots (A–C), different letters indicate significant differences among treatments (one-way ANOVA followed by Tukey’s HSD, p < 0.05; n = 3). For roots (D–F), differences relative to the MSO control were evaluated using Dunnett-adjusted contrasts (p < 0.05; n = 3).
Techniques Used: Cell Culture, Control
Figure Legend Snippet: Indole-3-acetic acid (IAA) is primarily synthesized from tryptophan through the indole-3-pyruvate (IPyA) pathway via tryptophan aminotransferase (TAA) and YUCCA flavin monooxygenase (YUC). Free IAA may be regulated through conjugation, catabolism, oxidative transformation and through feedback effects on tryptophan-derived metabolism. Kynurenine pathway metabolism proceeds through N-formyl-kynurenine and kynurenine, which occupies a central branch point between kynurenic acid formation via kynurenine aminotransferase (KAT) and downstream oxidative metabolism toward 3-hydroxyanthranilic acid (3-HAA) via kynurenine monooxygenase (KMO). Reactive oxygen species (ROS), temperature, drought, iron, and Fe 2+ are shown as potential stress and redox inputs that may influence auxin and kynurenine-associated metabolism. The pharmacological inhibitors used in this study are shown at their proposed targets: PF-04859989 at KAT, and RO-61-8048 and JM6 at kynurenine monooxygenase (KMO). Dashed arrows indicate proposed interactions linking auxin catabolism or oxidative transformation with kynurenine-associated metabolite accumulation and potential feedback on tryptophan-dependent auxin biosynthesis.
Techniques Used: Synthesized, Conjugation Assay, Transformation Assay, Derivative Assay
Related Articles
other:Article Title: Inhibition of the hERG potassium ion channel by different non-nucleoside human cytomegalovirus polymerase antiviral inhibitor series and the exploration of variations on a pyrroloquinoline core to reduce cardiotoxicity potential. Article Snippet: Many non-nucleoside human cytomegalovirus (HCMV) inhibitors have been reported in patent and scientific literature, however, none have reached commercialization despite the urgent need for new HCMV treatments.. Herein we report select compounds from different templates that all had low micromolar human ether-à-go-go (hERG) ion channel IC50 values.. We also describe a series of pyrroloquinoline derivatives that were designed and synthesized to understand the effect of various substitution on human cytomegalovirus (HCMV) polymerase activity, antiviral activity, and hERG inhibition. Activity Assay:Article Title: Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors. Article Snippet: Despite immune checkpoint inhibitors’ tremendous success in the treatment of tumors, the moderate response rate limits their widespread use.. Hematopoietic progenitor kinase 1 (HPK1) is served as an essential negative regulator of T-cell receptor, which has been identified as a promising target for enhancing antitumor immunity.. However, the development of a selective HPK1 inhibitor is still challenging. Article Title: Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. Article Snippet: .. General synthesis of ureas 14–26.a i R1 = H N N N H NH2 R 1 R1 = Cl; 1 N N N H NH R 1 O O R1 = H; 11 R1 = Cl; 12 R1 = cPr; 3 R1 = cPr; 13 ii 17–26 N N N H NH R 1 O NH N N N H NH O N X Y Z R 3 R1 = H; 14 R1 = Cl; 15 R1 = cPr; 16 R 2 aReagents and conditions: (i) Method B: phenyl chloroformate, pyridine, 0 °C to rt, 12.5 h; (ii) Method C: corresponding amine, triethylamine, chloroform, reflux, 16 h. This pyrazole series was initially identified from an HTS campaign with approximately 95,000 compounds from a diverse subset, selected to represent the broad chemical space of Pfizer’s Reflux:Article Title: Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. Article Snippet: .. General synthesis of ureas 14–26.a i R1 = H N N N H NH2 R 1 R1 = Cl; 1 N N N H NH R 1 O O R1 = H; 11 R1 = Cl; 12 R1 = cPr; 3 R1 = cPr; 13 ii 17–26 N N N H NH R 1 O NH N N N H NH O N X Y Z R 3 R1 = H; 14 R1 = Cl; 15 R1 = cPr; 16 R 2 aReagents and conditions: (i) Method B: phenyl chloroformate, pyridine, 0 °C to rt, 12.5 h; (ii) Method C: corresponding amine, triethylamine, chloroform, reflux, 16 h. This pyrazole series was initially identified from an HTS campaign with approximately 95,000 compounds from a diverse subset, selected to represent the broad chemical space of Pfizer’s In Vitro:Article Title: Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. Article Snippet: .. General synthesis of ureas 14–26.a i R1 = H N N N H NH2 R 1 R1 = Cl; 1 N N N H NH R 1 O O R1 = H; 11 R1 = Cl; 12 R1 = cPr; 3 R1 = cPr; 13 ii 17–26 N N N H NH R 1 O NH N N N H NH O N X Y Z R 3 R1 = H; 14 R1 = Cl; 15 R1 = cPr; 16 R 2 aReagents and conditions: (i) Method B: phenyl chloroformate, pyridine, 0 °C to rt, 12.5 h; (ii) Method C: corresponding amine, triethylamine, chloroform, reflux, 16 h. This pyrazole series was initially identified from an HTS campaign with approximately 95,000 compounds from a diverse subset, selected to represent the broad chemical space of Pfizer’s Article Title: Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors. Article Snippet: A series of 4-substituted pyrimido[4,5-d]azepines that are potent, selective 5-HT2C receptor partial agonists is described.. A rational medicinal chemistry design strategy to deliver CNS penetration coupled with SAR-based optimization of selectivity and agonist potency provided compounds with the desired balance of preclinical properties.. Lead compounds 17 (PF-4479745) and 18 (PF-4522654) displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5HT2B in relevant tissue-based assay systems. Selection:Article Title: Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors. Article Snippet: A series of 4-substituted pyrimido[4,5-d]azepines that are potent, selective 5-HT2C receptor partial agonists is described.. A rational medicinal chemistry design strategy to deliver CNS penetration coupled with SAR-based optimization of selectivity and agonist potency provided compounds with the desired balance of preclinical properties.. Lead compounds 17 (PF-4479745) and 18 (PF-4522654) displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5HT2B in relevant tissue-based assay systems. Concentration Assay:Article Title: Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors. Article Snippet: A series of 4-substituted pyrimido[4,5-d]azepines that are potent, selective 5-HT2C receptor partial agonists is described.. A rational medicinal chemistry design strategy to deliver CNS penetration coupled with SAR-based optimization of selectivity and agonist potency provided compounds with the desired balance of preclinical properties.. Lead compounds 17 (PF-4479745) and 18 (PF-4522654) displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5HT2B in relevant tissue-based assay systems. |
